CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

被引：0
|
作者：
Jing, P. [1 ,2 ]
Niu, Q. [2 ]
Deng, B. [3 ]
Liu, S. [1 ]
Wu, T. [4 ]
Gao, Z. [4 ]
Chang, A. H. [5 ]
Feng, X. [2 ]
Tong, C. [1 ]
机构：
[1] Beijing Boren Hosp, Dept Hematol, Beijing, Peoples R China
[2] Inst Hematol & Hosp Blood Dis, Tianjin, Peoples R China
[3] Beijing Boren Hosp, Cytol Lab, Beijing, Peoples R China
[4] Beijing Boren Hosp, Dept Bone Marrow Transplantat, Beijing, Peoples R China
[5] Tongji Univ, Sch Med, Clin Translat Res Ctr, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P2287
引用
收藏
页码：1723 / 1723
页数：1
相关论文
共 50 条
  • [41] Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma
    Samra, Bachar
    Alotaibi, Ahmad S.
    Short, Nicholas J.
    Khoury, Joseph D.
    Ravandi, Farhad
    Garris, Rebecca
    Jain, Nitin
    Konopleva, Marina
    Kantarjian, Hagop
    Jabbour, Elias
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) : E245 - E247
  • [42] Outcome of Adults with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    Samra, Bachar
    Alotaibi, Ahmad S.
    Short, Nicholas
    Khoury, Joseph
    Ravandi, Farhad
    Garris, Rebecca
    Jain, Nitin
    Konopleva, Marina
    Kantarjian, Hagop
    Jabbour, Elie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S170 - S170
  • [43] Bridging Chemotherapy Prior to CD19-Specific CAR T-Cell Therapy in Children/Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Shahid, S.
    Ramaswamy, K.
    Flynn, J.
    Mauguen, A.
    Boelens, J. -J.
    Forlenza, C.
    Kernan, N.
    Shukla, N.
    Steinherz, P.
    Sulis, M. L.
    Margossian, S.
    Perica, K.
    Park, J.
    Curran, K.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S88 - S88
  • [44] Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis
    Zhai, Yixin
    Hong, Ju
    Wang, Jinhuan
    Jiang, Yanan
    Wu, Wenqi
    Lv, Yangyang
    Guo, Jing
    Tian, Linyan
    Sun, Huimeng
    Li, Yuhang
    Li, Cheng
    Zhan, Hongjie
    Zhao, Zhigang
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (1-3) : 67 - 76
  • [45] Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
    Kantarjian, Hagop M.
    Stock, Wendy
    Cassaday, Ryan D.
    DeAngelo, Daniel J.
    Jabbour, Elias
    O'Brien, Susan M.
    Stelljes, Matthias
    Wang, Tao
    Paccagnella, M. Luisa
    Nguyen, Kevin
    Sleight, Barbara
    Vandendries, Erik
    Neuhof, Alexander
    Laird, A. Douglas
    Advani, Anjali S.
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2742 - 2754
  • [46] A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
    Srinagesh, Hrishikesh
    Jackson, Clayton
    Shiraz, Parveen
    Jeyakumar, Nikeshan
    Hamilton, Mark
    Egeler, Emily
    Mavroukakis, Sharon
    Kuo, Adam
    Cancilla, Juancarlos
    Sahaf, Bita
    Agarwal, Neha
    Kanegai, Alyssa
    Kramer, Anne Marijn
    Arai, Sally
    Bharadwaj, Sushma
    Dahiya, Saurabh
    Hosoya, Hitomi
    Johnston, Laura
    Kennedy, Vanessa
    Liedtke, Michaela
    Lowsky, Robert
    Mikkilineni, Lekha
    Negrin, Robert
    Rezvani, Andrew
    Sidana, Surbhi
    Shizuru, Judith
    Smith, Melody
    Weng, Wen-Kai
    Feldman, Steven
    Frank, Matthew J.
    Lee, Zachary
    Tagliaferri, Mary
    Marcondes, A. Mario
    Miklos, David
    Mackall, Crystal
    Muffly, Lori
    BLOOD, 2024, 144 (16) : 1689 - 1698
  • [47] CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia
    Yao, Yao
    Zhou, Jin
    Li, Yanting
    Shi, Sensen
    Yu, Lei
    Wu, Depei
    Wang, Ying
    ANNALS OF HEMATOLOGY, 2024, : 6031 - 6033
  • [48] The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
    Zhang, Xian
    Huang, Lefu
    Zhang, Gailing
    Su, Yunchao
    Hu, Xiaona
    Xia, Shulian
    Li, Jingjing
    Lu, Peihua
    BLOOD, 2022, 140 : 8884 - 8885
  • [49] Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia
    Liu, Sining
    Cui, Qingya
    Li, Zheng
    Cui, Wei
    Li, Mengyun
    Qiu, Huiying
    Xue, Shengli
    Chen, Suning
    Jin, Zhengming
    Miao, Miao
    Han, Yue
    Wang, Ying
    Zhu, Xiaming
    Yu, Lei
    Wu, Depei
    Tang, Xiaowen
    BLOOD, 2023, 142
  • [50] CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
    Vairy, Stephanie
    Garcia, Julia Lopes
    Teira, Pierre
    Bittencourt, Henrique
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3885 - 3898
12345